Hepatitis B treatment in resource poor settings: Time for action

Tropical Medicine and International Health

Volumn 15, Issue 1, 2010, Pages 2-4

  Thursz, Mark ^a   Cooke, Graham S ^a   Hall, Andrew J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antivirals; Hepatitis; Hepatitis B virus; Resource poor settings

Indexed keywords

ADEFOVIR; AFLATOXIN; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; TENOFOVIR;

DISEASE TREATMENT; DRUG; GLOBALIZATION; HEPATITIS; INFECTIOUS DISEASE; MORBIDITY; MORTALITY; SPATIOTEMPORAL ANALYSIS; VIRAL DISEASE;

CANCER RISK; CHRONIC HEPATITIS; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; ECHOGRAPHY; ELASTOGRAPHY; HEALTH CARE ACCESS; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION CONTROL; INFECTION RISK; LIVER BIOPSY; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; PATIENT SELECTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERNATIONAL COOPERATION; MEDICALLY UNDERSERVED AREA;

HEPATITIS B VIRUS;

EID: 72349092098     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02410.x     Document Type: Review

References (14)

1. Castera L, Forns X Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology 48, 835 847.
2. Chang MH, Chen CJ, Lai MS et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. New England Journal of Medicine 336, 1855 1859.
3. El-Sadr WM Abrams EJ (2007) Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings? AIDS 21, S65 S70.
4. European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of chronic hepatitis B. Journal of Hepatology 50, 227 242.
5. Hoffmann CJ Thio CL (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. The Lancet Infectious Diseases 7, 402 409.
6. Hotez PJ, Molyneux DH, Fenwick A et al. (2007) Control of neglected tropical diseases. New England Journal of Medicine 357, 1018 1027.
7. Kober K Van Damme W (2004) Scaling up access to antiretroviral treatment in South Africa: who will do the job? Lancet 364, 103 107.
8. Lai CL, Shouval D, Lok AS et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine 354, 1011 1020.
9. Lessells RJ, Main J Cooke GS (2008) HIV and hepatitis B co-infection in Africa: implications for the public health approach to ART. The Lancet Infectious Diseases 8, 210 211.
10. Liaw YF, Sung JJ, Chow WC et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. New England Journal of Medicine 351, 1521 1531.
11. Lok AS McMahon BJ (2007) Chronic hepatitis B. Hepatology 45, 507 539.
12. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R Wabinga H (2008) Part I: Cancer in Indigenous Africans - burden, distribution, and trends. The Lancet Oncology 9, 683 692.
13. Turner PC, Sylla A, Diallo MS, Castegnaro JJ, Hall AJ Wild CP (2002) The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. Journal of Gastroenterology and Hepatology 17, S441 S448.
14. Turner PC, Sylla A, Gong YY et al. (2005) Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 365, 1950 1956.